Physician profile
Himmat Singh Brar
NPI 1508328170
$3,590.85
in general payments reported to CMS, 2019-2025
23 companies · $904 in 2025
The $904 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,000 · 2022: $24.20 · 2023: $552 · 2024: $1,110 · 2025: $904.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,491 · Education: $76.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,490.65 |
| Education | $76.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,037.69 | 2021-2025 | Dificid, Zerbaxa |
| Abbvie INC. | $457.29 | 2023-2025 | Rinvoq, Skyrizi |
| Janssen Scientific Affairs, LLC | $418.55 | 2023-2025 | Stelara, Tremfya |
| Janssen Biotech, INC. | $404.01 | 2023-2025 | Tremfya, Stelara |
| Fujifilm Healthcare Americas Corporation | $160.00 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $154.20 | 2023-2025 | Entyvio, Gattex, Eohilia |
| Medtronic, INC. | $149.91 | 2023 | Manoscan |
| Ardelyx, INC. | $120.94 | 2024-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $111.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Olympus America INC. | $108.21 | 2023-2025 | Single Use Electrosurgical Knife Kd-655 |
| Micro-Tech Endoscopy USA, INC. | $89.18 | 2024 | Eyemax |
| Mallinckrodt Hospital Products INC. | $88.13 | 2024 | Terlivaz |
| Regeneron Healthcare Solutions, INC. | $58.27 | 2024-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $41.11 | 2024-2025 | Xifaxan |
| Gilead Sciences, INC. | $34.03 | 2024-2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $24.20 | 2022 | |
| Orphalan INC | $23.59 | 2024 | Cuvrior |
| Lilly USA, LLC | $22.61 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $20.89 | 2024 | Voquezna |
| Celgene Corporation | $19.47 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $17.48 | 2025 | |
| Erbe USA INC | $15.00 | 2023 | Erbe |
| Celltrion USA INC. | $14.86 | 2024 | Vegzelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himmat Brar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.